FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, namely to binding proteins specific for VEGF-A, and can be used in medicine. Binding protein containing up to four ancyrine repeat domains that are capable of inhibiting the binding of VEGF-A165 to VEGFR-2 is produced recombinantly.
EFFECT: invention allows to obtain effective inhibitor of VEGF-A165 without a number of side effects, for example, ability to inhibit angiogenesis in cells, in comparison with known peptide and non-peptide analogues.
16 cl, 4 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BINDING PROTEINS INHIBITING VEGF-A RECEPTOR INTERACTION | 2009 |
|
RU2550258C2 |
| MODIFIED BINDING PROTEINS, INHIBITING INTERACTION OF VEGF-A RECEPTOR | 2011 |
|
RU2605309C2 |
| ENGINEERED REPEAT PROTEIN BINDING WITH SERUM ALBUMINE | 2011 |
|
RU2625882C2 |
| IMPROVED N-TERMINAL CAPPING MODULES FOR CONSTRUCTED ANKYRIN REPEAT PROTEINS | 2011 |
|
RU2636552C2 |
| BINDING PROTEINS COMPRISING AT LEAST TWO REPEAT DOMAINS AGAINST HER2 | 2013 |
|
RU2664464C9 |
| RECOMBINANT BINDING PROTEINS AND THEIR USE | 2017 |
|
RU2778346C2 |
| INHIBITORS OF RECEPTORS OF TYPE 2 VESSEL ENDOTHELIUM GROWTH FACTOR | 2004 |
|
RU2402567C2 |
| ANTIANGIOGENIC INDUCER FUSION PROTEIN AND USING IT | 2012 |
|
RU2560589C2 |
| FUSED PROTEINS CONTAINING PDGF AND VEGF BINDING PARTS, AND METHODS FOR USE THEREOF | 2014 |
|
RU2692652C2 |
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
